Overview

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta [Neorecormon] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa